All In Biotech

NDA 020753 · Pfizer

Aromasin

Exemestane · Oral · Aromatase Inhibitor

NovelOrphan

Last checked: Nov 19, 2026Latest source record: Dec 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Oct 21, 1999

Approved uses

3

Original approval plus efficacy supplements

Registered trials

344

100 Phase 3, 56 recruiting

FAERS reports

21,520

16,483 serious, 2,534 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 24, 2025.

EXEMESTANE is an aromatase inhibitor indicated for: • adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to EXEMESTANE for completion of a total of five consecutive years of adjuvant hormonal therapy ( 14.1 ). • treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy ( 14.2 ). 1.1 Adjuvant Treatment of Postmenopausal Women EXEMESTANE is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to EXEMESTANE for completion of a total of five consecutive years of adjuvant hormonal therapy [see Clinical Studies (14.1) ]. 1.2 Advanced Breast Cancer in Postmenopausal Women EXEMESTANE is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies (14.2) ].

Mechanism: Breast cancer cell growth may be estrogen-dependent. Aromatase is the principal enzyme that converts androgens to estrogens both in pre- and postmenopausal women. While the main source of estrogen (primarily estradiol) is the ovary in premenopausal women, the principal source of circulating estrogens in postmenopausal women is from conversion of adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) by the aromatase enzyme in peripheral tissues. Exemestane is an irreversible, steroidal aromatase inactivator, structurally related to the natural...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • AROMASIN · EXEMESTANE 25MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Exemestane" as an intervention, any sponsor and status, largest first.

All 344 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue2,281
  • malignant neoplasm progression1,832
  • nausea1,749
  • arthralgia1,747
  • diarrhoea1,732
  • dyspnoea1,412
  • pain1,146
  • asthenia1,105
  • headache1,100
  • malaise1,086
  • cough1,042
  • vomiting1,009

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200499
2005234
2006253
2007256
2008337
2009378
2010588
2011521
2012618
2013930
20141,022
20151,753
20161,763
20171,454
20181,444
20191,716
20201,594
20211,257
20221,303
20231,281
20241,089
20251,001
2026628

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Aromasin (Exemestane)

2024 spending

$1.2M

Beneficiaries

116

646 claims

Per beneficiary

$10,045

$36.85 per unit

View as table
YearSpending
2020$2,358,708
2021$1,845,636
2022$1,290,233
2023$1,352,024
2024$1,165,163

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 369 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.